Early data show favourable safety and sustained target engagement for oral EP4 receptor antagonist

Study will assess whether microbiome therapy can protect gut diversity during transplantation

Phase 3 Mascot study reaches key milestone for potential first-in-class therapy

EC decision introduces first systemic option for adults with advanced SCAC

First‑in‑human phase 1/2a study launches in China and the US targeting advanced cancers

New funding will support the phase 2 expansion trial of THEO-260

DementAI prototype developed by Katalyze Data seeks to ease pressure on clinical teams

Company targets new approach to treating rheumatoid arthritis and systemic sclerosis

Early data show faster viral clearance and favourable safety in mild to moderate COVID‑19

New authorisation extends treatment to children with ISS, SGA and Noonan syndrome